Here are 1-2 brief analogies for Daxor (DXR):

• Like a Dexcom, but for blood volume measurement.
• Think of them as an Invitae, but for blood volume testing rather than genetic testing.

• BVA-100 Blood Volume Analyzer: A diagnostic blood test device that provides safe, accurate, and objective quantification of blood volume status and composition compared to patient-specific norms.

Daxor Corporation (DXR) sells primarily to other companies and organizations within the healthcare sector, rather than to individuals. Due to the nature of the medical device industry and competitive reasons, Daxor does not publicly disclose the specific names of its individual customer companies or institutions. Therefore, it is not possible to list specific publicly traded customer companies with their symbols.

However, based on the description of its BVA-100 Blood Volume Analyzer as a diagnostic blood test used in a broad range of medical and surgical conditions, Daxor's major customers fall into the following categories of healthcare providers:

1. Hospitals and Hospital Systems: Acute care hospitals, critical care units, operating rooms, and various specialized departments within hospital systems (e.g., cardiology, nephrology, intensive care) are primary users for diagnostic tools like the BVA-100 to manage blood volume in patients.
2. Specialized Clinics and Outpatient Centers: Clinics focusing on specific medical conditions that require precise blood volume management, such as heart failure clinics, dialysis centers, or surgical centers, would utilize this technology.
3. Research Institutions and Academic Medical Centers: These organizations often acquire advanced diagnostic equipment for clinical trials, medical research, and for use in their teaching hospitals, contributing to both patient care and medical advancement.

Michael Feldschuh, President and Chief Executive Officer

Michael Feldschuh has served as President and CEO of Daxor Corporation since 2017, joining the executive team in December 2014 after serving on the board of directors. He possesses over 25 years of experience on Wall Street and in the medical field. Prior to Daxor, he was a managing director and portfolio manager for Morgan Stanley for six years and a managing director of Millennium Partners for eight years. Michael also led his own hedge fund, Aristarc Capital, from 2009 to 2013, specializing in quantitative strategies. He began his career at D.E. Shaw & Co., where he worked with Jeff Bezos before Amazon's founding. Michael earned his bachelor's degree in pre-med studies at Columbia College, Columbia University.

Robert J. Michel, Chief Financial Officer

Robert J. Michel is a Certified Public Accountant with over 30 years of financial experience across manufacturing, advertising, and financial services. He gained his public accounting experience at Price Waterhouse in New York, a predecessor firm to PwC. Immediately before joining Daxor Corporation, Mr. Michel served as the CFO of Sher-Del Transfer and Relocation Services, a moving and storage company. He also served as CFO for seven years at Asta Funding, Inc., a publicly traded diversified financial services company. Mr. Michel holds a degree in Business Administration from Villanova University's School of Business and an MBA from St. John's University.

Jonathan Feldschuh, Chief Scientific Officer

Jonathan Feldschuh is a co-inventor of the BVA-100 and related patents, and is responsible for algorithmic design, statistical analysis, and patent applications for Daxor's next-generation blood volume analyzers. He developed black-box trading and analytical systems for Wall Street firms such as Morgan Stanley, Millennium Partners, and Shearson Lehman. Jonathan has also served as Chief Quantitative Officer for Aristarc Capital and as the CEO of Outseeker, a data-driven technology startup. He holds an A.B. in physics summa cum laude from Harvard University.

Dr. John Lynn Jefferies, Chief Medical Officer

Dr. John Lynn Jefferies serves as the Chief Medical Officer of Daxor Corporation. He is a board-certified and highly respected cardiologist.

Linda Cooper, Vice President Development & Operations

Linda Cooper has over 30 years of experience in product development and commercialization within the medical device industry. She has held senior leadership roles at major medical device companies, including OsteoCentric Technologies and Integra LifeSciences, where she oversaw multiple product launches through the entire development process, including hardware design, testing, regulatory clearance, and launch. Ms. Cooper is a seasoned professional with a background in bio-engineering and extensive regulatory experience with the FDA.

1. High Stock Volatility and Potential Overvaluation

   Daxor's stock has shown high volatility, with a reported volatility of 40.86% and a beta of 1.02, suggesting that its stock price may experience significant fluctuations. Furthermore, the company's valuation metrics indicate potential overvaluation; its P/E ratio of 71.13 is substantially higher than the historical median of 13.61, and its P/S ratio of 16.96 also points to a premium valuation compared to its historical median. These factors could pose risks to investors due to potential price instability and a possibly inflated stock price relative to its fundamentals.

2. Regulatory Challenges and Competitive Pressures

   As a medical device company, Daxor operates within a highly regulated environment, making it susceptible to inherent sector-specific risks. These include ongoing regulatory challenges related to product approvals, compliance, and potential changes in regulatory review processes, which could lead to delays in product market entry and affect revenue projections. Additionally, the company faces competitive pressures within the medical devices and instruments industry, which could impact its market share and pricing power for its blood volume measurement technology.

3. Operational Losses Amidst Strategic Investments and Commercialization Efforts

   Despite reporting significant revenue growth—a 45% increase in unaudited revenues for its operating division in 2025—Daxor incurred an operational loss of $268,598 in the same year. This loss is attributed to strategic investments in research and development for new products, expansion of commercial teams, and enhancements to production facilities. While these investments are aimed at future growth, the sustained operational losses indicate that the company has not yet achieved profitability from its core operations. The ability to effectively commercialize its next-generation Blood Volume Analyzer and increase market and physician acceptance remains crucial to overcoming these losses and achieving financial sustainability.

The addressable market for Daxor Corporation's main products and services, primarily focused on its BVA-100 Blood Volume Analyzer, is substantial across various medical conditions and regions.

The global Blood Volume Analyzer Market is projected to be approximately US$ 5.1 billion in 2024 and is expected to grow to around US$ 12.6 billion by 2034, demonstrating a compound annual growth rate (CAGR) of 9.5% during this forecast period. Another estimate for the global market size indicates it was approximately $2.5 billion in 2025 and is expected to reach over $4.5 billion by 2033. Furthermore, the market size is estimated to grow from USD 5.87 billion in 2025 to USD 14.42 billion by 2035, with a CAGR of 9.4%.

Regionally, North America is a significant market for blood volume analyzers. In 2024, North America led the global market, accounting for over 37.3% of the share and generating a revenue of US$ 1.9 billion. The United States specifically dominates this market due to the high prevalence of cardiovascular diseases, kidney disorders, and critical care cases that necessitate accurate blood volume measurements.

Daxor also highlights its own estimates for the total addressable global market for its blood volume measurement technology, stating it is over $12+ billion. The company further breaks down its addressable market by specific medical conditions, estimating market opportunities as follows:

• Heart Failure: $70 billion by 2030
• Hypertension: $219 billion
• Critical Care/Sepsis: $82-144 billion
• Surgical Blood Loss & Transfusions: $27.3 billion

Daxor Corporation (NASDAQ: DXR) is anticipated to drive future revenue growth over the next 2-3 years through several key initiatives and market expansions:

1. Expanded Adoption of BVA-100 and ezBVA Lab Services: Daxor is actively expanding the reach of its BVA-100 Blood Volume Analyzer and its ezBVA Lab service to new hospital systems and healthcare networks. The company reported signing 12 new accounts in 2024 and an additional three in early 2025. Recent expansions in late 2025 include an Upper Midwest Integrated Health System, an Ohio Academic Medical Center, and a Southwest Cardiology Group Practice, with a new diagnostic program launched in Tennessee in February 2026. These expansions target outpatient nephrology and heart failure management, demonstrating a growing customer base and market penetration.
2. Launch and Commercialization of the Next-Generation Portable Blood Volume Analyzer: In August 2025, Daxor received FDA 510(k) clearance for a next-generation portable Blood Volume Analyzer. This new device is designed to deliver results three times faster than the existing BVA-100 system and weighs only seven pounds, enhancing its utility for both military and civilian applications. The company is strategically deploying newly raised capital to manufacture and place these advanced units, which are expected to accelerate market adoption. The new analyzer is set to debut at the SCCM 2026 Critical Care Congress.
3. Growth in Sales of Single-Use Diagnostic Kits: Daxor operates on a "razor-and-blades" revenue model, where the consistent sales of disposable test kits for its BVA analyzers are a significant revenue driver. The number of diagnostic kits sold increased by 60.1% year-over-year in 2024 compared to 2023, following a 37% increase in the prior year, indicating a growing utilization of its installed base. This growth is particularly noted in applications for heart failure management and critical care.
4. Securing and Executing Military Contracts: Daxor has a 2-year, $2.5 million contract with the U.S. Department of Defense to develop analyzers aimed at improving combat casualty care. Revenue generated from military contracts contributed to the company's growth in 2025, highlighting a specialized and ongoing revenue stream that leverages its technology for critical applications.
5. Introduction of Glofil (Kidney Filtration Rate Drug): As part of a strategy to integrate a key supplier and bring 100% of production in-house, Daxor anticipates adding Glofil, a kidney filtration rate drug, to its product portfolio. This expansion into a new diagnostic drug is expected to broaden Daxor's offerings and create an additional revenue stream within the projected timeframe.

Share Issuance

• In January 2026, Daxor completed a registered direct offering, issuing 765,958 shares of common stock at $11.75 per share.
• The offering generated approximately $9 million in gross proceeds and $8.14 million in net proceeds after placement agent fees and expenses.
• The net proceeds from this offering are intended for general corporate purposes, including working capital.

Inbound Investments

• A registered direct offering in January 2026 involved the purchase and sale of shares with "fundamental investors," securing approximately $9 million in gross proceeds for the company.

Outbound Investments

• In December 2025, Daxor sold its remaining investment portfolio positions to concentrate 100% of its resources on the primary blood volume business.
• For the fiscal year ended December 31, 2025, Daxor recorded net realized gains on investment activity of $745,334.
• For the fiscal year ended December 31, 2024, the company had net realized gains on investment activity of $1,359,163.

Capital Expenditures

• In 2025, Daxor's operating division experienced an operating loss of $268,598, attributed to strategic investments in research and development for the 2025 product launch, expanding commercial sales teams, and enhancing production facilities for its next-generation analyzers.
• In 2024, the company invested $1,614,124 into its operating division, focusing on research, development, sales, and overhead, specifically for the 2025 product launch, commercial sales team expansion, and production facilities and inventory for next-generation blood volume analyzers.
• Daxor is working on internalizing manufacturing processes for its products to improve profitability.